Patients diagnosed with age-related wet macular degeneration within 6 months may be eligible for this research clinical trial studying an investigational device that slowly releases Ranibizumab into the eye. Leading scientists have designed the Port Delivery System for Sustained Delivery of Ranibizumab (PDS). This surgically implanted, refillable, ocular device releases Lucentis over a period of months. So the objective of this study is to learn if the Lucentis delivery device, refilled as needed (approximately 4 or 5 time a year) is as effective and well-tolerated as monthly Lucentis injections.
An Efficacy and Safety Study of Surgically Implanted Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab 0.2mg, 0.8mg, or 2mg vs. Monthly Intravitreal Injections of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization from Age Related Macular Degeneration.
Sites: Middleburg Heights
Study Coordinator: Susan Rath